Imipramine for vestibular dysfunction in panic disorder: a prospective case series
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos de neuro-psiquiatria (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200011 |
Resumo: | OBJECTIVE: The purpose of this study was to evaluate the efficacy and effectiveness of imipramine on the treatment of comorbid chronic dizziness and panic disorder. METHOD: Nine patients with panic disorder and agoraphobia associated with chronic dizziness underwent otoneurological screening and were treated with a 3-months course of imipramine. Anxiety levels were measured with the Hamilton Anxiety Scale (HAM-A), dizziness levels were evaluated using the Dizziness Handicap Inventory (DHI), and panic severity and treatment outcome were assessed with the Clinical Global Impression Scale (CGI). RESULTS: At the baseline 33.3% (n=3) had a bilateral peripheral deficit vestibulopathy, the mean scores for HAM-A were 27.2±10.4, for DHI were 51.7±22.7, and for CGI-S were 4.8±0.9. All patients had a significant reduction in their HAM-A (11.1±5.5, p=0.008), DHI (11.5±8.1, p=0.008) and CGI-I (1.8±0.7, p=0.011) levels after 3-months imipramine treatment (mean=72.2±23.2 mg/day). CONCLUSION: This study found a decrease in anxiety levels and in the impact of dizziness in the patients' quality of life after a 3-months treatment course with imipramine. |
id |
ABNEURO-1_acffc1c8ad51d0e0268eb334280f24d7 |
---|---|
oai_identifier_str |
oai:scielo:S0004-282X2011000200011 |
network_acronym_str |
ABNEURO-1 |
network_name_str |
Arquivos de neuro-psiquiatria (Online) |
repository_id_str |
|
spelling |
Imipramine for vestibular dysfunction in panic disorder: a prospective case seriesdizzinesspanic disorderimipramineanxiety disordersOBJECTIVE: The purpose of this study was to evaluate the efficacy and effectiveness of imipramine on the treatment of comorbid chronic dizziness and panic disorder. METHOD: Nine patients with panic disorder and agoraphobia associated with chronic dizziness underwent otoneurological screening and were treated with a 3-months course of imipramine. Anxiety levels were measured with the Hamilton Anxiety Scale (HAM-A), dizziness levels were evaluated using the Dizziness Handicap Inventory (DHI), and panic severity and treatment outcome were assessed with the Clinical Global Impression Scale (CGI). RESULTS: At the baseline 33.3% (n=3) had a bilateral peripheral deficit vestibulopathy, the mean scores for HAM-A were 27.2±10.4, for DHI were 51.7±22.7, and for CGI-S were 4.8±0.9. All patients had a significant reduction in their HAM-A (11.1±5.5, p=0.008), DHI (11.5±8.1, p=0.008) and CGI-I (1.8±0.7, p=0.011) levels after 3-months imipramine treatment (mean=72.2±23.2 mg/day). CONCLUSION: This study found a decrease in anxiety levels and in the impact of dizziness in the patients' quality of life after a 3-months treatment course with imipramine.Academia Brasileira de Neurologia - ABNEURO2011-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200011Arquivos de Neuro-Psiquiatria v.69 n.2a 2011reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/S0004-282X2011000200011info:eu-repo/semantics/openAccessMezzasalma,Marco AndreMathias,Kátia de VasconcellosNascimento,IsabellaValença,Alexandre M.Nardi,Antonio E.eng2011-04-26T00:00:00Zoai:scielo:S0004-282X2011000200011Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2011-04-26T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse |
dc.title.none.fl_str_mv |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
title |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
spellingShingle |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series Mezzasalma,Marco Andre dizziness panic disorder imipramine anxiety disorders |
title_short |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
title_full |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
title_fullStr |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
title_full_unstemmed |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
title_sort |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
author |
Mezzasalma,Marco Andre |
author_facet |
Mezzasalma,Marco Andre Mathias,Kátia de Vasconcellos Nascimento,Isabella Valença,Alexandre M. Nardi,Antonio E. |
author_role |
author |
author2 |
Mathias,Kátia de Vasconcellos Nascimento,Isabella Valença,Alexandre M. Nardi,Antonio E. |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Mezzasalma,Marco Andre Mathias,Kátia de Vasconcellos Nascimento,Isabella Valença,Alexandre M. Nardi,Antonio E. |
dc.subject.por.fl_str_mv |
dizziness panic disorder imipramine anxiety disorders |
topic |
dizziness panic disorder imipramine anxiety disorders |
description |
OBJECTIVE: The purpose of this study was to evaluate the efficacy and effectiveness of imipramine on the treatment of comorbid chronic dizziness and panic disorder. METHOD: Nine patients with panic disorder and agoraphobia associated with chronic dizziness underwent otoneurological screening and were treated with a 3-months course of imipramine. Anxiety levels were measured with the Hamilton Anxiety Scale (HAM-A), dizziness levels were evaluated using the Dizziness Handicap Inventory (DHI), and panic severity and treatment outcome were assessed with the Clinical Global Impression Scale (CGI). RESULTS: At the baseline 33.3% (n=3) had a bilateral peripheral deficit vestibulopathy, the mean scores for HAM-A were 27.2±10.4, for DHI were 51.7±22.7, and for CGI-S were 4.8±0.9. All patients had a significant reduction in their HAM-A (11.1±5.5, p=0.008), DHI (11.5±8.1, p=0.008) and CGI-I (1.8±0.7, p=0.011) levels after 3-months imipramine treatment (mean=72.2±23.2 mg/day). CONCLUSION: This study found a decrease in anxiety levels and in the impact of dizziness in the patients' quality of life after a 3-months treatment course with imipramine. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-04-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200011 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200011 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0004-282X2011000200011 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
dc.source.none.fl_str_mv |
Arquivos de Neuro-Psiquiatria v.69 n.2a 2011 reponame:Arquivos de neuro-psiquiatria (Online) instname:Academia Brasileira de Neurologia instacron:ABNEURO |
instname_str |
Academia Brasileira de Neurologia |
instacron_str |
ABNEURO |
institution |
ABNEURO |
reponame_str |
Arquivos de neuro-psiquiatria (Online) |
collection |
Arquivos de neuro-psiquiatria (Online) |
repository.name.fl_str_mv |
Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia |
repository.mail.fl_str_mv |
||revista.arquivos@abneuro.org |
_version_ |
1754212770437398528 |